Back to results
US 2022/0064602 A1Published application
Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
AssigneeChildren's Hospital Medical Center
InventorsJames Wells, Kyle McCracken
Life of this patent
Estimating the term…
Abstract
The instant disclosure relates to methods for converting mammalian definitive endoderm (DE) cells into specific tissue(s) or organ(s) through directed differentiation. In particular, the disclosure relates to formation of gastric fundus tissue and/or organoids formed from differentiated definitive endoderm.
Claims11
-18. (canceled)
A human fundal gastric organoid (hFGO) characterized by:
- a) MUC5AC-positive surface mucous cells and MUC6-positive mucous neck cells;
- b) endocrine cells expressing ghrelin (GHRL), somatostatin (SST), and histamine;
- c) chief cells expressing MIST1, pepsinogen A (PGA5), and pepsinogen C (PGC);
- d) parietal cell-dense glands;
- e) parietal cells expressing ATP4A, ATP4B, and GIF;
- and
- f) wherein the hFGO exhibits a greater number of parietal cells and elevated expression of ATP4A, ATP4B, and GIF relative to an hFGO that has not been treated with a MEK inhibitor.
4 more elements
Dependencies are inferred from the claim text.